Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896798 | 0.94 | NPC1 (0.56) | NPC1CCR5POLBLMNAMAP4K4 | |
| SCHEMBL31705840 | 0.82 | CCR5 (0.50) | CCR5MAP4K4KCNH2SIGMAR1 | |
| SCHEMBL13434079 | 0.82 | CCR5 (0.63) | CCR5KCNH2SIGMAR1 | |
| SCHEMBL2404816 | 0.81 | CCR5 (0.66) | CCR5POLBCTBP2SIGMAR1KMT2A | |
| SCHEMBL2407533 | 0.81 | KCNH2 (0.49) | NPC1CCR5POLBKCNH2SIGMAR1 | |
| SCHEMBL12569388 | 0.80 | CTBP2 (0.54) | NPC1POLBCTBP2 | |
| SCHEMBL2404555 | 0.80 | CCR5 (0.44) | CCR5KCNH2SIGMAR1KMT2AOPRD1 | |
| SCHEMBL31705847 | 0.79 | LOXL2 (0.54) | CCR5MAP4K4SIGMAR1KMT2A | |
| SCHEMBL19518893 | 0.79 | NPC1 (0.42) | NPC1POLBLMNACTBP2SIGMAR1 | |
| SCHEMBL21880658 | 0.79 | NPC1 (0.42) | NPC1POLBLMNACTBP2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | NPC1 1540/4885CCR5 2055/4885POLB 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.